News | November 07, 2011

SNM Launches Web Site for Nuclear Medicine and Molecular Imaging Patients

November 7, 2011 – The Society of Nuclear Medicine (SNM) launched a new patient-focused website, discoverMI.org, to provide patients with information about nuclear medicine and molecular imaging and how it can play a critical role in the detection, treatment and management of diseases.

“Many times patients referred for a nuclear medicine or molecular imaging studies are nervous about what to expect,” said George Segall, M.D., SNM president. “By providing information and explaining the benefits of the study in an easy-to-understand format, we can offer them both help and support.”

The website focuses on three common disease areas: heart disease, cancer and brain disease. For each area, specific types of disease are detailed along with the various nuclear and molecular imaging procedures that are associated with each. General information on molecular imaging, an extensive glossary and a video library are also included on the site. Additionally, patients can stay up to date on the latest in molecular imaging news through Facebook and Twitter pages designed to complement the site.

DiscoverMI.org is supported by several patient advocacy groups that are a part of SNM’s Patient Advocacy Advisory Board (PAAB), including the Alzheimer’s Association, the American Thyroid Association, the Leukemia and Lymphoma Society, the Ovarian Cancer Alliance of Arizona, the Ovarian Cancer National Alliance, the American Heart Association, the Men’s Health Network and the Thyroid Cancer Survivors’ Association.

“I am thrilled that this comprehensive resource for patients is now available,” said Betsy de Parry, a member of SNM’s PAAB and author of Adventures in Cancer Land. Laurel Pracht, SNM PAAB member and patient advocate for the Ovarian Cancer National Alliance, added, “As a patient, it is critical to have access to user-friendly information about what is available for someone with your disease. The website provides information about both what is currently available in molecular imaging and how it may affect you.”

More than 16 million Americans undergo nuclear and molecular imaging and therapy procedures each year for a variety of conditions, including cancer, cardiovascular disease, neurological conditions and other physiological problems. Nuclear and molecular imaging procedures are an invaluable way to gather medical information that would otherwise be unavailable, require surgery or necessitate more expensive diagnostic tests.

For more information: www.snm.org

 

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init